Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds
Luis Prats-Sanchez,Pol Camps-Renom,Philip S Nash,Duncan Wilson,Gareth Ambler,Jonathan G Best,Marina Guasch-Jiménez,Anna Ramos-Pachón,Alejandro Martinez-Domeño,Álvaro Lambea-Gil,Garbiñe Ezcurra Díaz,Daniel Guisado-Alonso,Houwei Du,Rustam Al-Shahi Salman,Hans Rolf Jäger,Gregory Y Lip,Hakan Ay,Simon Jung,Natan M Bornstein,Thomas Gattringer,Sebastian Eppinger,Dianne H van Dam-Nolen,Masatoshi Koga,Kazunori Toyoda,Felix Fluri,Thanh G Phan,Velandai K Srikanth,Ji Hoe Heo,Hee-Joon Bae,Peter J Kelly,Toshio Imaizumi,Julie Staals,Sebastian Köhler,Yusuke Yakushiji,Dilek Necioglu Orken,Eric E Smith,Joanna M Wardlaw,Francesca M Chappell,Stephen D Makin,Jean-Louis Mas,David Calvet,Régis Bordet,Christopher P Chen,Roland Veltkamp,Nagaendran Kandiah,Robert J Simister,Frank-Erik De Leeuw,Stefan T Engelter,Nils Peters,Yannie O Soo,Annaelle Zietz,Jeroen Hendrikse,Werner H Mess,David J Werring,Joan Marti-Fabregas,Microbleeds International Collaborative Network (MICON)
DOI: https://doi.org/10.1212/WNL.0000000000209173
IF: 9.9
2024-04-09
Neurology
Abstract:Background and objectives: The association between statin use and the risk of intracranial hemorrhage (ICrH) following ischemic stroke (IS) or transient ischemic attack (TIA) in patients with cerebral microbleeds (CMBs) remains uncertain. This study investigated the risk of recurrent IS and ICrH in patients receiving statins based on the presence of CMBs. Methods: We conducted a pooled analysis of individual patient data from the Microbleeds International Collaborative Network, comprising 32 hospital-based prospective studies fulfilling the following criteria: adult patients with IS or TIA, availability of appropriate baseline MRI for CMB quantification and distribution, registration of statin use after the index stroke, and collection of stroke event data during a follow-up period of ≥3 months. The primary endpoint was the occurrence of recurrent symptomatic stroke (IS or ICrH), while secondary endpoints included IS alone or ICrH alone. We calculated incidence rates and performed Cox regression analyses adjusting for age, sex, hypertension, atrial fibrillation, previous stroke, and use of antiplatelet or anticoagulant drugs to explore the association between statin use and stroke events during follow-up in patients with CMBs. Results: In total, 16,373 patients were included (mean age 70.5 ± 12.8 years; 42.5% female). Among them, 10,812 received statins at discharge, and 4,668 had 1 or more CMBs. The median follow-up duration was 1.34 years (interquartile range: 0.32-2.44). In patients with CMBs, statin users were compared with nonusers. Compared with nonusers, statin therapy was associated with a reduced risk of any stroke (incidence rate [IR] 53 vs 79 per 1,000 patient-years, adjusted hazard ratio [aHR] 0.68 [95% CI 0.56-0.84]), a reduced risk of IS (IR 39 vs 65 per 1,000 patient-years, aHR 0.65 [95% CI 0.51-0.82]), and no association with the risk of ICrH (IR 11 vs 16 per 1,000 patient-years, aHR 0.73 [95% CI 0.46-1.15]). The results in aHR remained consistent when considering anatomical distribution and high burden (≥5) of CMBs. Discussion: These observational data suggest that secondary stroke prevention with statins in patients with IS or TIA and CMBs is associated with a lower risk of any stroke or IS without an increased risk of ICrH. Classification of evidence: This study provides Class III evidence that for patients with IS or TIA and CMBs, statins lower the risk of any stroke or IS without increasing the risk of ICrH.